Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 23, 2024
Colorectal
cancer
(CRC),
as
one
of
the
malignant
tumors
with
highest
incidence
and
mortality
rates
worldwide
in
recent
years,
originating
primarily
from
mucosal
tissues
colon
or
rectum,
has
potential
to
rapidly
develop
into
invasive
cancer.
Its
pathogenesis
is
complex,
involving
a
multitude
factors
including
genetic
background,
lifestyle,
dietary
habits.
Early
detection
treatment
are
key
improving
survival
for
patients
CRC.
However,
pervasive
problem
that
can
become
severely
resistant
treatment,
which
greatly
increases
complexity
challenge
treatment.
Therefore,
unraveling
overcoming
resistance
CRC
focus
research.
Mitochondria,
energy
centers
cell,
play
crucial
role
cellular
metabolism,
supply,
apoptosis
process.
In
CRC,
Mitochondrial
dysfunction
not
only
impairs
normal
cell
function
but
also
promotes
tumor
resistance.
deep
understanding
relationship
between
mitochondrial
mechanisms
development,
well
by
it
chemotherapy
drugs,
development
targeted
therapies,
enhancing
drug
efficacy,
outcomes
quality
life
patients.
World Journal of Gastrointestinal Oncology,
Journal Year:
2024,
Volume and Issue:
16(11), P. 4354 - 4368
Published: Oct. 25, 2024
The
relevant
mechanism
of
tumor-associated
macrophages
(TAMs)
in
the
treatment
colorectal
cancer
patients
with
immune
checkpoint
inhibitors
(ICIs)
is
discussed,
and
application
prospects
TAMs
reversing
tolerance
ICIs
are
discussed
to
provide
a
reference
for
related
studies.
As
class
drugs
widely
used
clinical
tumor
immunotherapy,
can
act
on
regulatory
molecules
cells
that
play
an
inhibitory
role
-
checkpoints
kill
tumors
form
response
by
activating
variety
system.
sensitivity
different
types
ICI
varies
greatly.
phenotype
function
microenvironment
closely
efficacy
ICIs.
regulate
phenotypic
TAMs,
also
affect
therapy.
important
resistance,
making
full
use
this
target
as
therapeutic
strategy
expected
improve
immunotherapy
prognosis
cancer.
Discover Oncology,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Nov. 18, 2024
Autophagy
is
a
crucial
mechanism
for
maintaining
cellular
homeostasis
and
responding
to
environmental
stress,
it
closely
linked
tumor
drug
resistance.
Through
multi-omics
analysis,
this
study
explores
the
expression
patterns,
functions,
potential
role
of
autophagy-related
gene
Angiotensinogen
(AGT)
in
colorectal
cancer
(CRC),
particularly
relation
chemotherapy
This
first
compared
AGT
between
CRC
normal
tissues
using
GTEx
TCGA
databases.
Differences
were
assessed
Wilcoxon
Rank
Sum
Tests,
prognostic
impact
was
evaluated
through
univariate
Cox
survival
analysis
meta-analysis.
Functional
enrichment
performed
limma
fgsea
packages.
Drug
sensitivity
conducted
based
on
CTRP
database,
while
immune
infiltration
CIBERSORT
ESTIMATE
methods.
Spatial
transcriptomic
characteristics
explored
10x
Visium
technology
deconvolution
investigate
correlation
levels
cell
content.scRNA-seq
data
from
sourced
Tumor
Immune
Single
Cell
Hub
(TISCH).Functional
annotation
with
Single-sample
set
(SSGSEA),
pseudotime
Monocle
2
mapped
their
developmental
trajectories.
The
inhibitors
treatment
analyzed
drug-target
Mendelian
randomization.Finally,
Phenome-Wide
Association
Study
(PheWAS)
evaluate
genetic
associations
side
effects
inhibitors.
significantly
higher
associated
shorter
recurrence-free
(RFS).
signaling
pathways
markedly
enriched
high
group.
positively
correlated
resistance
chemotherapeutic
agents
such
as
gemcitabine,
cisplatin,
paclitaxel,
5-fluorouracil.
revealed
that
predominantly
expressed
malignant
regions.
Single-cell
identified
21
distinct
subpopulations
across
13
major
types.
samples,
especially
fibroblast
C6
subpopulation.
Tumor-related
C1,
C5,
C6,
C8
subpopulations.
Pseudotime
these
subpopulations,
terminal
stages.Drug-target
randomization
indicated
negative
causal
relationship
risk
both
heart
failure(ORdrug
=
0.950,
95%
CI,
0.912–0.990;
P
0.014)
CRC(ORdrug
0.874,
CI:
0.792–0.964;
0.007).PheWAS
showed
no
other
traits,
indicating
its
specificity
low
effects.
Elevated
chemotherapy,
inhibition
may
offer
therapeutic
avenue
cancer.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 9, 2024
Colorectal
cancer
(CRC)
is
a
leading
cause
of
cancer-related
deaths
globally.
The
heterogeneity
the
tumor
microenvironment
significantly
influences
patient
prognosis,
while
diversity
cells
shapes
its
unique
characteristics.
A
comprehensive
analysis
molecular
profile
crucial
for
identifying
novel
targets
drug
sensitivity
and
uncovering
pathophysiological
mechanisms
underlying
CRC.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 23, 2024
Colorectal
cancer
(CRC),
as
one
of
the
malignant
tumors
with
highest
incidence
and
mortality
rates
worldwide
in
recent
years,
originating
primarily
from
mucosal
tissues
colon
or
rectum,
has
potential
to
rapidly
develop
into
invasive
cancer.
Its
pathogenesis
is
complex,
involving
a
multitude
factors
including
genetic
background,
lifestyle,
dietary
habits.
Early
detection
treatment
are
key
improving
survival
for
patients
CRC.
However,
pervasive
problem
that
can
become
severely
resistant
treatment,
which
greatly
increases
complexity
challenge
treatment.
Therefore,
unraveling
overcoming
resistance
CRC
focus
research.
Mitochondria,
energy
centers
cell,
play
crucial
role
cellular
metabolism,
supply,
apoptosis
process.
In
CRC,
Mitochondrial
dysfunction
not
only
impairs
normal
cell
function
but
also
promotes
tumor
resistance.
deep
understanding
relationship
between
mitochondrial
mechanisms
development,
well
by
it
chemotherapy
drugs,
development
targeted
therapies,
enhancing
drug
efficacy,
outcomes
quality
life
patients.
